8-K: Invivyd to Pursue Rapid Immunobridging Pathway for Potential COVID-19 Treatment EUA

Invivyd plans to submit an Emergency Use Authorization (EUA) application for pemivibart as a COVID-19 treatment for immunocompromised individuals, leveraging a rapid immunobridging pathway.

Summary

• Invivyd is seeking an EUA for pemivibart to treat COVID-19 in moderately to severely immunocompromised individuals.
• The company will use an immunobridging approach, similar to the one used for its existing EUA for pemivibart as a preventative measure.
• This approach leverages data from the STAMP trial of adintrevimab and the ongoing CANOPY trial of pemivibart.
• The treatment EUA application will focus on individuals for whom other COVID-19 treatment options are not suitable.
• Invivyd plans to initiate a small clinical trial to confirm safety, pharmacokinetics, and clinical virology after submitting the EUA request.
• The company anticipates having approximately 100,000 doses available in the second half of 2024.
• Invivyd is maintaining its 2024 net product revenue guidance of $150-$200 million and year-end cash guidance of at least $75 million, despite the potential treatment EUA.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a new pathway for a potential treatment EUA and maintaining financial guidance. However, there are risks and uncertainties associated with the regulatory process and manufacturing, which temper the overall sentiment.

Positives

• The immunobridging pathway offers a faster route to potential EUA approval for COVID-19 treatment.
• The company is leveraging existing data and technology to expedite the process.
• There is a focus on addressing the unmet medical needs of immunocompromised individuals.
• Invivyd has a manufacturing plan in place to produce approximately 100,000 doses by the second half of 2024.
• The company is maintaining its existing financial guidance despite the potential for additional revenue from treatment sales.

Negatives

• The potential treatment EUA was not considered in the previously issued financial guidance.
• The company is still in the process of considering options to expand and accelerate product availability.
• The EUA is only authorized for the duration of the COVID-19 emergency declaration.

Risks

• The company's ability to effectively utilize the immunobridging pathway is not guaranteed.
• There are uncertainties related to the regulatory authorization or approval process.
• Unexpected safety or efficacy data could impact the outcome of clinical trials.
• The company relies on third parties for virus assay creation, product testing, and manufacturing.
• The EUA for PEMGARDA could be revoked or revised by the FDA.
• The company may not be able to maintain a continued acceptable safety, tolerability and efficacy profile of PEMGARDA.
• There is a risk that PEMGARDA may not demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants.
• The company may not be able to provide sufficient commercial supply of PEMGARDA to meet market demand.
• The company may not be able to obtain and maintain third-party coverage and adequate reimbursement for PEMGARDA.
• The company's ability to continue as a going concern is a risk.
• The company may not have adequate funding to meet future operating expenses and capital expenditure requirements.

Future Outlook

Invivyd plans to submit an EUA application for pemivibart for COVID-19 treatment and initiate a compact clinical trial focused on confirmatory safety, pharmacokinetics, and clinical virology. The company anticipates having approximately 100,000 doses available in the second half of 2024 and is considering options to expand and accelerate product availability. The company is maintaining its 2024 financial guidance.

Management Comments

• Marc Elia, Chairman of the Invivyd Board of Directors, stated that they are glad to align with the FDA on a rapid pathway to address the medical needs of immunocompromised people.
• Mark Wingertzahn, SVP of Clinical Development and Medical Affairs, noted that treatment of active COVID-19 infection is well suited for an infused antibody therapy.
• Brian Koffman, MDCM (retired), MS Ed, Co-Founder, Executive Vice President and Chief Medical Officer of the CLL Society, emphasized the need for new treatment options for immunocompromised individuals.

Industry Context

This announcement reflects the ongoing need for effective COVID-19 treatments, particularly for vulnerable populations like the immunocompromised. It also highlights the continued relevance of monoclonal antibody therapies in combating the virus, even as new variants emerge. The use of an immunobridging pathway is a strategic move to accelerate the approval process, which is becoming more common in the industry.

Comparison to Industry Standards

• The use of immunobridging is a common strategy to accelerate drug approval, particularly in infectious diseases, and has been used by other companies such as Regeneron and Eli Lilly for their COVID-19 antibody treatments.
• The focus on immunocompromised patients aligns with the industry's recognition of the need for specialized treatments for vulnerable populations, similar to how companies like AstraZeneca have developed preventative therapies for this group.
• The manufacturing plan of 100,000 doses in the second half of 2024 is a significant step, but it will need to be compared to the production capacity of other companies in the monoclonal antibody space, such as Roche and GSK, to assess its competitiveness.
• The financial guidance provided by Invivyd is consistent with the need for companies to provide clear financial outlooks, but it will need to be compared to the revenue and cash positions of other biotech companies in the same stage of development, such as Vir Biotechnology and Adagio Therapeutics.

Stakeholder Impact

• Shareholders may view the potential treatment EUA as a positive development, potentially increasing the company's revenue and market value.
• Immunocompromised patients could benefit from a new treatment option, addressing an unmet medical need.
• Employees may be impacted by the increased workload associated with the EUA application and clinical trial.
• Suppliers may see increased demand for raw materials and manufacturing services.

Next Steps

• Invivyd plans to submit a COVID-19 treatment EUA request to the FDA.
• The company will initiate a compact clinical trial focused on confirmatory safety, pharmacokinetics, and clinical virology.
• Invivyd will continue to consider options to expand and accelerate product availability.

Key Dates

Keywords

COVID-19, EUA, pemivibart, immunobridging, monoclonal antibody, immunocompromised, treatment, FDA, SARS-CoV-2, PrEP